Lytix Biopharma Feed

2025-05-09 07:10:00 Lytix Biopharma AS: Lytix Biopharma: Invitation to Q1 2025 Results Presentation

2025-05-09 07:00:00 Lytix Biopharma: Invitation to Q1 2025 Results Presentation

2025-04-29 14:27:01 Lytix Biopharma AS reshuffled its Board after the Ordinary General Meeting 5,30 NOK | -0,38%

2025-04-29 14:19:50 Lytix Biopharma AS: Minutes from Ordinary General Meeting and Election of New Board of Directors 5,30 NOK | -0,38%

2025-04-22 21:33:42 Lytix Biopharma AS: Recommendation from the Nomination and Compensation Committee to the Annual General Meeting, resignation by board Chair 5,38 NOK | +7,60%

2025-04-22 21:18:16 Lytix Biopharma AS: Recommendation from the Nomination and Compensation Committee to the Annual General Meeting, resignation by board Chair 5,38 NOK | +7,60%

2025-04-10 07:20:00 Lytix Biopharma AS: Notice of Annual General Meeting on 29 April 2025 4,87 NOK | -1,02%

2025-04-10 07:10:00 Lytix Biopharma AS: Notice of Annual General Meeting on 29 April 2025 4,87 NOK | -1,02%

2025-04-10 07:05:00 Lytix Biopharma AS: Annual Report for 2024 4,87 NOK | -1,02%

2025-04-10 07:00:00 Lytix Biopharma AS: Annual Report for 2024 4,87 NOK | -1,02%

2025-02-13 08:05:00 Lytix Biopharma AS: Lytix Biopharma Q4 2024: Solid clinical results strengthen the path to Phase III and further advancements in 2025 5,58 NOK | -2,45%

2025-02-13 08:00:00 Lytix Biopharma Q4 2024: Solid clinical results strengthen the path to Phase III and further advancements in 2025 5,58 NOK | -2,45%

2025-02-12 08:05:00 Lytix Biopharma AS: Lytix Biopharma receives Notice of Allowance for U.S. patent application covering its LTX-315 clinical program 5,72 NOK | -0,69%

2025-02-12 08:00:00 LYTIX: Lytix Biopharma receives Notice of Allowance for U.S. patent application covering its LTX-315 clinical program 5,72 NOK | -0,69%

2025-02-07 09:06:39 Lytix Biopharma AS: Lytix Biopharma: Invitation to Q4 2024 Results Presentation 5,80 NOK | +2,47%

2025-02-07 08:56:14 Lytix Biopharma: Invitation to Q4 2024 Results Presentation 5,80 NOK | +2,47%

2025-01-22 08:05:00 Lytix Biopharma AS - Licensing partner Verrica Pharmaceuticals presents clinical data with LTX-315 at the 2025 Winter Clinical Dermatology Conference 5,40 NOK | +0,75%

2025-01-22 08:00:00 Lytix Biopharma AS - Licensing partner Verrica Pharmaceuticals presents clinical data with LTX-315 at the 2025 Winter Clinical Dermatology Conference 5,40 NOK | +0,75%

2025-01-15 16:01:38 Lytix Biopharma AS - New share capital registered 5,72 NOK | +1,06%

2025-01-15 13:05:06 Lytix Biopharma AS - New share capital registered 5,72 NOK | +1,06%

2025-01-07 19:18:04 Lytix Biopharma AS - Cancellation of Subsequent Offering 5,86 NOK | +0,34%

2025-01-07 19:12:15 Lytix Biopharma AS - Cancellation of Subsequent Offering 5,86 NOK | +0,34%

2025-01-02 11:45:34 LYTIX: Financial calendar 5,96 NOK | +1,36%

2025-01-02 11:45:34 LYTIX: Finansiell kalender 5,96 NOK | +1,36%

2024-12-27 17:24:41 Lytix Biopharma AS - Mandatory Notification of Trade - Redelivery of Lent Shares to Closely Associated Party of a Primary Insider

2024-12-23 17:26:06 Lytix Biopharma AS - New share capital registered

2024-12-23 17:03:47 Lytix Biopharma AS - New share capital registered

2024-12-17 15:53:15 Lytix Biopharma AS - Mandatory Notification of Trade - Share Lending by Closely Associated Party of a Primary Insider 5,82 NOK | -16,86%

2024-12-17 08:05:00 Lytix Biopharma AS: Key information relating to potential subsequent offering 5,82 NOK | -16,86%

2024-12-17 08:05:00 Lytix Biopharma AS - Mandatory notification of trade by Primary Insiders and close associates 5,82 NOK | -16,86%

2024-12-17 08:00:00 Lytix Biopharma AS: Key information relating to potential subsequent offering 5,82 NOK | -16,86%

2024-12-17 08:00:00 Lytix Biopharma AS - Mandatory notification of trade by Primary Insiders and close associates 5,82 NOK | -16,86%

2024-12-17 00:30:37 Lytix Biopharma AS: Private placement and retail offer via PrimaryBid successfully completed 7,00 NOK | -2,78%

2024-12-17 00:27:04 Lytix Biopharma AS: Private placement and retail offer via PrimaryBid successfully completed 7,00 NOK | -2,78%

2024-12-16 17:09:15 Lytix Biopharma AS: Lytix Biopharma - Lytix launches Retail Offering via Primary Bid and Nordnet, in parallel with private placement 5,82 NOK | -16,86%

2024-12-16 17:04:06 Lytix Biopharma AS: Contemplated private placement and retail offer via PrimaryBid 5,82 NOK | -16,86%

2024-12-16 16:45:30 Lytix Biopharma - Lytix lanserer emisjon for småinvestorer via PrimaryBid og Nordnet, parallelt med en rettet emisjon 5,82 NOK | -16,86%

2024-12-16 16:45:30 Lytix Biopharma - Lytix launches Retail Offering via Primary Bid and Nordnet, in parallel with private placement 5,82 NOK | -16,86%

2024-12-16 16:32:32 Lytix Biopharma AS: Contemplated private placement and retail offer via PrimaryBid 5,82 NOK | -16,86%

2024-11-26 12:54:00 LYTIX: Lytix Biopharma presents updated phase II results from skin cancer study (BCC) at the DNB Nordic Healthcare Conference 6,82 NOK | +8,60%

2024-11-21 15:48:15 Lytix Biopharma AS: Lytix Biopharma - Licensing partner Verrica Pharmaceuticals announces pricing of underwritten public offering, raising approximately USD 42 million upon completion 6,40 NOK | +7,02%

2024-11-21 15:40:15 Lytix Biopharma - Licensing partner Verrica Pharmaceuticals announces the pricing of a underwritten public offering, raising approximately USD 42 million upon completion 6,40 NOK | +7,02%

2024-11-19 07:05:00 Lytix Biopharma AS: Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization 5,84 NOK | -8,75%

2024-11-19 07:00:00 Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization 5,84 NOK | -8,75%

2024-11-12 10:33:58 Lytix Biopharma AS: Lytix Biopharma: Invitation to Q3 2024 Results Presentation 6,82 NOK | -1,16%

2024-11-12 10:10:30 Lytix Biopharma: Invitation to Q3 2024 Results Presentation 6,82 NOK | -1,16%

2024-11-06 22:23:47 Lytix Biopharma AS: First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo - promising use of Lytix cancer treatment in patients with early-stage melanoma 6,80 NOK | +12,96%

2024-11-06 22:23:47 Lytix Biopharma AS: Lovende fase II-studie i pasienter med tidligfase føflekkreft startet opp ved Radiumhospitalet - første pasient behandlet med Lytix' kreftbehandling 6,80 NOK | +12,96%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Lytix Biopharma

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden